Видео ютуба по тегу Speaker: Georgina Long

Women in Science with Professor Georgina Long AO
Women in Science with Professor Georgina Long AO
Power of Giving Unconditionally | 29-06-2021 | Georgina Long
Power of Giving Unconditionally | 29-06-2021 | Georgina Long
RELATIVITY-020: dose comparison of nivolumab and relatlimab in melanoma
RELATIVITY-020: dose comparison of nivolumab and relatlimab in melanoma
Neoadjuvant therapy: a game-changer in melanoma
Neoadjuvant therapy: a game-changer in melanoma
RELATIVITY-098: nivolumab and relatlimab in stage III-IV melanoma
RELATIVITY-098: nivolumab and relatlimab in stage III-IV melanoma
Melanoma news from ESMO 19
Melanoma news from ESMO 19
NeoPeLe: neoadjuvant pembrolizumab and lenvatinib in resectable stage III melanoma
NeoPeLe: neoadjuvant pembrolizumab and lenvatinib in resectable stage III melanoma
Preventing melanoma through public health education
Preventing melanoma through public health education
MPA Melanoma Symposium Series - Webinar 3: Melanoma Treatments and Clinical Trials
MPA Melanoma Symposium Series - Webinar 3: Melanoma Treatments and Clinical Trials
WCF Nov16 Film: 12 - Brahma Kumaris Speaker
WCF Nov16 Film: 12 - Brahma Kumaris Speaker
Implementing neoadjuvant therapy into routine clinical practice for melanoma
Implementing neoadjuvant therapy into routine clinical practice for melanoma
Treating patients with melanoma who progressed on anti-PD-L1 with lenvatinib and pembrolizumab
Treating patients with melanoma who progressed on anti-PD-L1 with lenvatinib and pembrolizumab
Long-term outcomes of nivo vs. nivo/ipi in melanoma brain metastases: ABC trial data
Long-term outcomes of nivo vs. nivo/ipi in melanoma brain metastases: ABC trial data
Novel approaches in melanoma
Novel approaches in melanoma
Georgina Rejected The Guy, Then..🥶
Georgina Rejected The Guy, Then..🥶
Potential of ADCs in treating melanoma
Potential of ADCs in treating melanoma
Expert Report on novel data in (neo)adjuvant treatment of melanoma from ASCO 2022
Expert Report on novel data in (neo)adjuvant treatment of melanoma from ASCO 2022
IOB-032/PN-E40: pembrolizumab with a IO102-IO103 in melanoma and SCCHN
IOB-032/PN-E40: pembrolizumab with a IO102-IO103 in melanoma and SCCHN
Challenges associated with implementing ctDNA approaches in melanoma
Challenges associated with implementing ctDNA approaches in melanoma
Highlights in skin cancer at ASCO 2024
Highlights in skin cancer at ASCO 2024
Pre-treatment ctDNA linked to increased risk of early recurrence in IO-treated melanoma
Pre-treatment ctDNA linked to increased risk of early recurrence in IO-treated melanoma